BMJ  2005;331:1101 (12 November), doi:10.1136/bmj.331.7525.1101

News

NICE to issue faster guidance on use of drugs by NHS

Susan Mayor

London

The first 150 words of the full text of this article appear below.

The National Institute for Health and Clinical Excellence (NICE), which advises the NHS in England on the use of medical treatments, has developed a more rapid process for assessment that will be used initially for lifesaving medicines, including several cancer drugs.

The new "single technology appraisal" process will enable NICE to develop guidance on drugs selected for rapid assessment within eight weeks—much more quickly than the current average of 18 months. It will initially be applied to lifesaving drugs that have already been licensed and to new lifesaving medicines close to the time that they first become available.

In the faster appraisal system, NICE will ask for a single submission of evidence from the manufacturer of the drug being appraised. The institute will then independently assess this evidence and move rapidly to the final stage of the process—in which organisations can appeal against the decision—in cases for which the draft . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Article

Journal criticises Vioxx study for omitting three heart attacks
Janice Hopkins Tanne
BMJ 2005 331: 1423. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

  • Tanne, J. H. (2005). Journal criticises Vioxx study for omitting three heart attacks. BMJ 331: 1423-1423 [Full text]  
Access jobs at BMJ Careers
Whats new online at Student BMJ